Venture Life Group plc Stock

Equities

VLG

GB00BFPM8908

Pharmaceuticals

Market Closed - London S.E. 11:35:22 2024-05-13 am EDT 5-day change 1st Jan Change
40.5 GBX -3.11% Intraday chart for Venture Life Group plc +1.25% +20.90%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2023 51.41M 64.56M Sales 2024 * 55.02M 69.09M Capitalization 51.23M 64.33M
Net income 2023 - 0 Net income 2024 * 2M 2.51M EV / Sales 2023 0.82 x
Net Debt 2023 * 10.47M 13.14M Net Debt 2024 * 9.17M 11.52M EV / Sales 2024 * 1.1 x
P/E ratio 2023
49.3 x
P/E ratio 2024 *
22 x
Employees 153
Yield 2023 *
-
Yield 2024 *
-
Free-Float 83.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.11%
1 week+1.25%
1 month+5.19%
3 months+8.72%
6 months+44.64%
Current year+20.90%
More quotes
1 week
40.20
Extreme 40.2
41.80
1 month
36.80
Extreme 36.8
42.91
Current year
32.30
Extreme 32.3
42.91
1 year
27.00
Extreme 27
42.91
3 years
23.00
Extreme 23
105.00
5 years
20.00
Extreme 20
118.00
10 years
20.00
Extreme 20
118.00
More quotes
Managers TitleAgeSince
Founder 60 05-12-11
Director of Finance/CFO 37 21-11-30
Director/Board Member - 14-03-23
Members of the board TitleAgeSince
Founder 60 05-12-11
Director/Board Member 60 22-10-09
Director/Board Member - 14-03-23
More insiders
Date Price Change Volume
24-05-13 40.5 -3.11% 88,559
24-05-10 41.8 +2.58% 36,617
24-05-09 40.75 0.00% 44,719
24-05-08 40.75 +0.62% 101,801

Delayed Quote London S.E., May 13, 2024 at 11:35 am EDT

More quotes
Venture Life Group PLC is a United Kingdom-based consumer self-care company. The principal activities of the Company are the development, manufacturing, and commercialization of healthcare products, including medical devices, food supplements and cosmetics for the ageing population. The Company's product portfolio includes products, such as the UltraDEX and Dentyl oral care product ranges; the Balance Activ range in the area of women's intimate healthcare; the Lift Glucose and Glucogel product ranges for hypoglycaemia; Gelclair, Xonrid, and Pomi-T for oncology support products provide symptomatic relief for some of the side effects associated with cancer and its treatment; the Procto-eze Plus product ranges for hemorrhoids, and other Dermatology products. The Company operates through two segments: Venture Life Brands and Customer Brands. The Company's subsidiaries include Venture Life Limited, Lubatti Limited, Periproducts Limited, HL Healthcare Ltd, and Venture Life Healthcare Ltd.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.405 GBP
Average target price
0.76 GBP
Spread / Average Target
+87.65%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW